RxDoctor Payments Data

Meagan Smoyer, NP

Family · Hyannis, MANPI 1871072546

Payments from drug & device makers

$4,784in general payments, 2019–2025

Across 163 payments — averaging $29.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Astellas Pharma US Inc$583
  • Sumitomo Pharma America, Inc.$332
  • Teleflex LLC$269
  • Novo Nordisk$213
  • Johnson & Johnson$201
  • plus $2K from 37 others

What the payments were for

  • Speaking & faculty fees$311%
  • Travel & lodging$83918%
  • Food & beverage$3,61576%
  • Education$2996%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,784 in reported general payments places this provider in the 95th percentile of 2,320 family providers in Massachusetts.

See all family providers in Massachusetts

Medicare billing

Part B allowed, 2024
$39,147
Medicare patients
202
Services billed
4,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron181$239,335
MyrbetriqMirabegron51$48,039
Estradiol227$14,958
PremarinEstrogens, Conjugated22$9,550
Methenamine Hippurate113$7,315
YuvafemEstradiol20$3,286
Clobetasol Propionate48$2,995
Cefpodoxime Proxetil61$1,950
Cephalexin89$1,358
Tamsulosin Hcl74$1,167
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst131$1,039
Solifenacin Succinate11$828
Testosterone Cypionate24$691
Oxybutynin Chloride ErOxybutynin Chloride16$650
Alfuzosin Hcl ErAlfuzosin Hcl11$390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$332$239,335181 claims
Astellas Pharma US IncMyrbetriq$583$48,03951 claims
PfizerPremarin$32$9,55022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,320 family providers in Massachusetts.

Other family in Hyannis

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →